Is there a role for menopausal hormone therapy in the management of postmenopausal osteoporosis?
Serge Rozenberg, Nasser M Al-Daghri, M. Aubertin-Leheudre, Maria Luisa Brandi, A. Cano, Peter Collins, C. Cooper, A. R. Genazzani, T. Hillard, John Kanis, J. -M. Kaufman, I. Lambrinoudaki, A. Laslop, Eugene McCloskey, Santiago Palacios, D. Prieto-Alhambra, Jean Yves Reginster, Rene Rizzoli, Giuseppe Rosano, ... Nicholas C. Harvey. (2020). Is there a role for menopausal hormone therapy in the management of postmenopausal osteoporosis? Osteoporosis International. 31(12), pp. 2271-2286. https://doi.org/10.1007/s00198-020-05497-8
|Authors||Serge Rozenberg, Nasser M Al-Daghri, M. Aubertin-Leheudre, Maria Luisa Brandi, A. Cano, Peter Collins, C. Cooper, A. R. Genazzani, T. Hillard, John Kanis, J. -M. Kaufman, I. Lambrinoudaki, A. Laslop, Eugene McCloskey, Santiago Palacios, D. Prieto-Alhambra, Jean Yves Reginster, Rene Rizzoli, Giuseppe Rosano, F. Tremollienes and Nicholas C. Harvey|
We provide an evidence base and guidance for the use of menopausal hormone therapy (MHT) for the maintenance of skeletal health and prevention of future fractures in recently menopausal women. Despite controversy over associated side effects, which has limited its use in recent decades, the potential role for MHT soon after menopause in the management of postmenopausal osteoporosis is increasingly recognized. We present a narrative review of the benefits versus risks of using MHT in the management of postmenopausal osteoporosis. Current literature suggests robust anti-fracture efficacy of MHT in patients unselected for low BMD, regardless of concomitant use with progestogens, but with limited evidence of persisting skeletal benefits following cessation of therapy. Side effects include cardiovascular events, thromboembolic disease, stroke and breast cancer, but the benefit-risk profile differs according to the use of opposed versus unopposed oestrogens, type of oestrogen/progestogen, dose and route of delivery and, for cardiovascular events, timing of MHT use. Overall, the benefit-risk profile supports MHT treatment in women who have recently (< 10 years) become menopausal, who have menopausal symptoms and who are less than 60 years old, with a low baseline risk for adverse events. MHT should be considered as an option for the maintenance of skeletal health in women, specifically as an additional benefit in the context of treatment of menopausal symptoms, when commenced at the menopause, or shortly thereafter, in the context of a personalized benefit-risk evaluation.
|Journal citation||31 (12), pp. 2271-2286|
|Digital Object Identifier (DOI)||https://doi.org/10.1007/s00198-020-05497-8|
|Open access||Published as ‘gold’ (paid) open access|
File Access Level
|Publication process dates|
|Deposited||28 Apr 2021|
|License: CC BY-NC 4.0|
|File access level: Open|
3views this month
0downloads this month